

# Jos A Paramo

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7897874/jose-a-paramo-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40  
papers

729  
citations

15  
h-index

26  
g-index

44  
ext. papers

879  
ext. citations

4.4  
avg, IF

3.72  
L-index

#	Paper	IF	Citations
40	Hemostatic Biomarkers and Volumetry Help to Identify High-Risk Abdominal Aortic Aneurysms. <i>Life</i> , <b>2022</b> , 12, 823	3	
39	The Role of Circulating Biomarkers in Peripheral Arterial Disease. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	7
38	Association of SDF1 and MMP12 with Atherosclerosis and Inflammation: Clinical and Experimental Study. <i>Life</i> , <b>2021</b> , 11,	3	1
37	Microvascular thrombosis and clinical implications. <i>Medicina Clínica (English Edition)</i> , <b>2021</b> , 156, 609-614	0.3	
36	[Microvascular thrombosis and clinical implications]. <i>Medicina Clínica</i> , <b>2021</b> , 156, 609-614	1	3
35	Circulating TIMP-1 is associated with hematoma volume in patients with spontaneous intracranial hemorrhage. <i>Scientific Reports</i> , <b>2020</b> , 10, 10329	4.9	1
34	Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD). <i>Journal of Extracellular Vesicles</i> , <b>2020</b> , 9, 1729646	16.4	17
33	Pulmonary Embolism, Pulmonary Microvascular Thrombosis, or Both in COVID-19?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2020</b> , 26, 1076029620933953	3.3	6
32	Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients. <i>Journal of Critical Care</i> , <b>2019</b> , 51, 117-121	4	3
31	Differences in Venous Thromboembolism Prevention and Outcome between Hospitalized Patients with Solid and Hematologic Malignancies. <i>TH Open</i> , <b>2019</b> , 3, e153-e156	2.7	
30	Phenotypic Screening To Discover Novel Chemical Series as Efficient Antihemorrhagic Agents. <i>ACS Medicinal Chemistry Letters</i> , <b>2018</b> , 9, 428-433	4.3	2
29	Selective increase of cardiomyocyte derived extracellular vesicles after experimental myocardial infarction and functional effects on the endothelium. <i>Thrombosis Research</i> , <b>2018</b> , 170, 1-9	8.2	9
28	Matrix metalloproteinase-10 deficiency delays atherosclerosis progression and plaque calcification. <i>Atherosclerosis</i> , <b>2018</b> , 278, 124-134	3.1	20
27	SP453MATRIX METALLOPROTEINASE-10 AND TISSUE INHIBITOR OF METALLOPROTEINASE-1 (TIMP-1) AS EARLY PREDICTORS OF NEPHROPATHY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, i500-i500	4.3	
26	CM352 Reduces Brain Damage and Improves Functional Recovery in a Rat Model of Intracerebral Hemorrhage. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	14
25	Arterial spin labeling MRI is able to detect early hemodynamic changes in diabetic nephropathy. <i>Journal of Magnetic Resonance Imaging</i> , <b>2017</b> , 46, 1810-1817	5.6	47
24	Reduced high-density lipoprotein cholesterol: A valuable, independent prognostic marker in peripheral arterial disease. <i>Journal of Vascular Surgery</i> , <b>2017</b> , 66, 1527-1533.e1	3.5	11

23	Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study. <i>European Journal of Haematology</i> , <b>2016</b> , 97, 128-36	3.8	2
22	Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction. <i>BMC Neurology</i> , <b>2015</b> , 15, 111	3.1	10
21	Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation. <i>Liver International</i> , <b>2015</b> , 35, 1590-6	7.9	37
20	Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2015</b> , 21, 297-308	3.3	4
19	Functional MMP-10 is required for efficient tissue repair after experimental hind limb ischemia. <i>FASEB Journal</i> , <b>2015</b> , 29, 960-72	0.9	14
18	Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/C-X-C chemokine receptor 4 axis. <i>Hepatology</i> , <b>2015</b> , 62, 166-78	11.2	44
17	Matrix metalloproteinase 10 is associated with disease severity and mortality in patients with peripheral arterial disease. <i>Journal of Vascular Surgery</i> , <b>2015</b> , 61, 428-35	3.5	31
16	Discovery and safety profiling of a potent preclinical candidate, (4-[4-[[[3R)-3-(hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-methylbenzamide) (CM-352), for the prevention and treatment of hemorrhage. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 2465-88	8.3	10
15	Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 2465-88	8.3	17
14	The CXCR4/SDF1 axis improves muscle regeneration through MMP-10 activity. <i>Stem Cells and Development</i> , <b>2014</b> , 23, 1417-27	4.4	24
13	Matrix metalloproteinase-10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair. <i>Liver International</i> , <b>2014</b> , 34, e257-70	7.9	37
12	Association between serum tissue inhibitor of matrix metalloproteinase-1 levels and mortality in patients with severe brain trauma injury. <i>PLoS ONE</i> , <b>2014</b> , 9, e94370	3.7	27
11	Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document". <i>Blood Transfusion</i> , <b>2013</b> , 11, 585-610	3.6	75
10	Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis. <i>Nephrology</i> , <b>2010</b> , 15, 178-83	2.2	26
9	Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. <i>Kidney International</i> , <b>2010</b> , 78, 1275-80	9.9	31
8	Topical issues in venous thromboembolism. <i>Drugs</i> , <b>2010</b> , 70 Suppl 2, 11-8	12.1	11
7	Corrigendum to Preliminary characterisation of the promoter of the human p22phox gene: Identification of a new polymorphism associated with hypertension [FEBS Lett. 542 (2003) 27B1]. <i>FEBS Letters</i> , <b>2010</b> , 584, 4709-4709	3.8	
6	Integrating soluble biomarkers and imaging technologies in the identification of vulnerable atherosclerotic patients. <i>Biomarker Insights</i> , <b>2007</b> , 1, 165-73	3.5	3

5	Integrating Soluble Biomarkers and Imaging Technologies in the Identification of Vulnerable Atherosclerotic Patients. <i>Biomarker Insights</i> , <b>2006</b> , 1, 117727190600100	3.5	1
4	Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer. <i>Clinical and Translational Oncology</i> , <b>2005</b> , 7, 150-5	3.6	12
3	Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. <i>Atherosclerosis</i> , <b>2003</b> , 170, 269-76	3.1	85
2	Vitamins C and E downregulate vascular VEGF and VEGFR-2 expression in apolipoprotein-E-deficient mice. <i>Atherosclerosis</i> , <b>2003</b> , 171, 67-73	3.1	56
1	Purification and characterization of a variant of human prothrombin: prothrombin Segovia. <i>Thrombosis Research</i> , <b>1997</b> , 85, 465-77	8.2	7